Promising Results in Slowing Parkinson’s Disease Progression

French researchers conduct a one-year study using a GLP-1 receptor agonist, a drug similar to Ozempic, showing promising results in slowing the progression of Parkinson’s disease. This development brings hope to the half a million Americans diagnosed with the illness and offers a glimmer of hope for individuals affected by Parkinson’s disease.